
Cagrilintide (CagriSema)
CagriSema combines the investigational amylin drug cagrilintide with the approved drug semaglutide. In the main 68-week phase 3 trial, adults with obesity lost on average 20.4% of their body weight, compared with 3.0% on placebo, and in an East Asian trial it beat semaglutide alone by 6.5 percentage points. It also lowered blood sugar in type 2 diabetes. Neither CagriSema nor cagrilintide is FDA-approved, and heart outcome results are not yet available.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with obesity or type 2 diabetes who qualify for and choose to join a registered clinical trial; everyone else can ask a doctor about approved options, which include semaglutide on its own
Common dosing range
No approved dose. Phase 3 trials mainly studied cagrilintide 2.4 mg plus semaglutide 2.4 mg once weekly, and lower levels of 1.7 mg or 1.0 mg of each
When to expect effects
The dose was raised over 8 to 16 weeks; weight loss was measured at 68 weeks and blood sugar at 40 to 68 weeks
Watch out for
Not FDA-approved and cannot be prescribed outside a trial. FDA says cagrilintide cannot be used in compounding and is not a component of any FDA-approved drug, so products sold online are unapproved and unverified. Stomach side effects affected about 3 in 4 people in the main trials
What is it
Cagrilintide is an investigational drug that is not FDA-approved for any use, alone or in CagriSema, its once-weekly combination with semaglutide, so neither can be prescribed outside a clinical trial, and any product sold now as cagrilintide (including vials labeled "for research use only") is unapproved and unverified. FDA says cagrilintide cannot be used in compounding under federal law, is not a component of any FDA-approved drug and has not been found safe and effective for any condition. Cagrilintide is a long-acting version of amylin, a hormone released by the pancreas with insulin. Its developer, Novo Nordisk, has published phase 3 trials of CagriSema in adults with obesity and in type 2 diabetes in 2025 and 2026; a heart outcomes trial (REDEFINE 3), trials in children and adolescents, and phase 3 trials of cagrilintide on its own (the RENEW trials) are still running on ClinicalTrials.gov. Semaglutide, the other half of CagriSema, is an approved drug (Ozempic, Wegovy), but the combination is not.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
weight loss in adults with obesity without diabetes Good Evidence | 17.3 percentage points more weight loss than placebo at 68 weeks (REDEFINE 1); 6.5 percentage points more than semaglutide alone (REDEFINE 5) | Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes | Measured at 68 weeks |
weight loss in adults with type 2 diabetes Good Evidence | 10.4 percentage points more weight loss than placebo at 68 weeks | Adults with type 2 diabetes and a BMI of 27 or more | Measured at 68 weeks |
blood sugar (HbA1c) in type 2 diabetes Good Evidence | HbA1c 1.7 percentage points lower than placebo (REIMAGINE 1); 0.16 points lower than semaglutide alone (REIMAGINE 2) | Adults with type 2 diabetes, including those on metformin or basal insulin | Measured at 40 to 68 weeks |
weight loss with cagrilintide alone Limited Evidence | 3.0 to 7.8 percentage points more weight loss than placebo at 26 weeks | Adults with obesity without diabetes | Measured at 26 weeks |
weight loss in adults with obesity without diabetes
- Effect
- 17.3 percentage points more weight loss than placebo at 68 weeks (REDEFINE 1); 6.5 percentage points more than semaglutide alone (REDEFINE 5)
- Best fit
- Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes
- Time
- Measured at 68 weeks
weight loss in adults with type 2 diabetes
- Effect
- 10.4 percentage points more weight loss than placebo at 68 weeks
- Best fit
- Adults with type 2 diabetes and a BMI of 27 or more
- Time
- Measured at 68 weeks
blood sugar (HbA1c) in type 2 diabetes
- Effect
- HbA1c 1.7 percentage points lower than placebo (REIMAGINE 1); 0.16 points lower than semaglutide alone (REIMAGINE 2)
- Best fit
- Adults with type 2 diabetes, including those on metformin or basal insulin
- Time
- Measured at 40 to 68 weeks
weight loss with cagrilintide alone
- Effect
- 3.0 to 7.8 percentage points more weight loss than placebo at 26 weeks
- Best fit
- Adults with obesity without diabetes
- Time
- Measured at 26 weeks
Evidence for 4 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
weight loss in adults with obesity without diabetes
Disease adjunctIn REDEFINE 1, a 68-week phase 3 trial of 3417 adults with obesity, or overweight with a weight-related condition, and without diabetes, CagriSema (2.4 mg of each drug weekly) lowered body weight by an average of 20.4%, compared with 3.0% on placebo. In REDEFINE 5, 331 adults in Japan and Taiwan (24% with type 2 diabetes) lost 18.4% on CagriSema, compared with 11.9% on semaglutide alone (also estimated as if treatment was taken as intended). In REDEFINE 9, 309 adults on the lower levels of 1.7 mg or 1.0 mg of each drug lost 20.7% and 21.0%, compared with 2.0% on placebo, estimated as if everyone had stayed on treatment. All trials were funded by Novo Nordisk. They did not test heart attacks, strokes or deaths, and the published results do not cover what happens after stopping.
Bottom line: Larger average weight loss than semaglutide alone in a head-to-head trial; no heart outcome data yet.
weight loss in adults with type 2 diabetes
Disease adjunctIn REDEFINE 2, a 68-week phase 3 trial in 12 countries, 1206 adults with type 2 diabetes (HbA1c 7% to 10%) and a BMI of 27 or more received CagriSema (2.4 mg of each weekly) or placebo with lifestyle advice. Body weight fell by 13.7% on CagriSema and 3.4% on placebo, and 73.5% reached an HbA1c of 6.5% or less, compared with 15.9% on placebo. The trial was funded by Novo Nordisk and did not test diabetes complications or heart outcomes.
Bottom line: Meaningful weight loss in type 2 diabetes, though smaller than in people without diabetes.
blood sugar (HbA1c) in type 2 diabetes
Biomarker supportIn three phase 3 trials, CagriSema lowered HbA1c in adults with type 2 diabetes. In REIMAGINE 2 (2713 adults on metformin with or without an SGLT2 inhibitor, 68 weeks), HbA1c fell by 1.91 percentage points with 2.4 mg of each drug, compared with 1.75 with semaglutide 2.4 mg alone, a small but statistically significant difference. In REIMAGINE 1 (189 adults on diet and exercise, 40 weeks), it fell by 1.8 points, compared with 0.1 on placebo. In REIMAGINE 3 (274 adults on basal insulin, 40 weeks), it fell by 2.33 points, compared with 0.66 on placebo, with no severe low blood sugar reported. All were funded by Novo Nordisk.
Bottom line: It lowers blood sugar well, but only slightly more than semaglutide alone.
weight loss with cagrilintide alone
Disease adjunctIn a 26-week phase 2 trial in ten countries, 706 adults with obesity, or overweight with high blood pressure or abnormal blood fats, and without diabetes were assigned to cagrilintide 0.3 to 4.5 mg weekly, liraglutide 3.0 mg daily or placebo. Weight fell by 6.0% to 10.8% depending on dose, compared with 3.0% on placebo, and the 4.5 mg dose produced more weight loss than liraglutide 3.0 mg daily (10.8% vs 9.0%). The trial was funded by Novo Nordisk and was short. Phase 3 trials of cagrilintide on its own (RENEW 1, 2 and 4) are still running.
Bottom line: On its own, cagrilintide caused moderate weight loss in one short phase 2 trial.
How it works
How to take it
What to track
Bottom line: Strong weight loss in trials, but an unapproved combination: a registered clinical trial is the only legitimate way to receive it now.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Boxed warning on the semaglutide label, which applies to the semaglutide in CagriSema: semaglutide caused thyroid C-cell tumors in rodents, and it is unknown whether it causes medullary thyroid cancer in people. It must not be used with a personal or family history of medullary thyroid cancer or MEN 2.
Other warnings on the semaglutide label, which apply to the semaglutide in CagriSema: pancreatitis, gallbladder disease, dehydration leading to kidney injury, low blood sugar with insulin or a sulfonylurea, severe stomach side effects (not recommended with severe gastroparesis), serious allergic reactions, worsening of diabetic eye disease (retinopathy) in people with type 2 diabetes, a faster heart rate, and food entering the lungs during anesthesia or deep sedation. Whether adding cagrilintide changes these risks is not established.
Stopping treatment. In REDEFINE 5, 10% stopped CagriSema, compared with 6% who stopped semaglutide alone. In the phase 2 trial of cagrilintide alone, 10% stopped treatment permanently, at similar rates across groups, and 4% stopped because of adverse events.
Unknown long-term and heart safety. The heart outcomes trial of CagriSema (REDEFINE 3, about 7100 adults with heart disease) is still running, with its primary completion estimated on ClinicalTrials.gov as September 2027.
Unapproved products of unknown quality. FDA says cagrilintide cannot be used in compounding under federal law, is not a component of any FDA-approved drug and has not been found safe and effective for any condition. FDA warns that illegally marketed GLP-1 drugs sold online may be counterfeit or contain the wrong ingredients or the wrong amount.
Who should avoid it
- Anyone outside a registered clinical trial, because neither cagrilintide nor CagriSema is approved and cagrilintide cannot be compounded
- People with a personal or family history of medullary thyroid cancer or MEN 2 (a contraindication on the semaglutide label)
- People who are pregnant, planning a pregnancy or breastfeeding: the semaglutide label says it may cause fetal harm and advises stopping at least 2 months before a planned pregnancy; for breastfeeding, it has no data for semaglutide injection and does not recommend breastfeeding with Wegovy tablets, and no data on cagrilintide are published
Pregnancy & breastfeeding
Pregnancy: no data on cagrilintide or CagriSema in pregnancy are published. The label of semaglutide, one of the two drugs in CagriSema, says it may cause fetal harm and, for weight reduction, advises stopping it at least 2 months before a planned pregnancy because it stays in the body a long time. Breastfeeding: no data on cagrilintide in breast milk are published; the Wegovy label says breastfeeding is not recommended during treatment with Wegovy tablets.
Interactions
Based on the label of semaglutide, which CagriSema contains (class-based, not a finding for cagrilintide itself): the Wegovy label says use with insulin or an insulin secretagogue such as a sulfonylurea may increase the risk of low blood sugar, including severe low blood sugar, and that reducing the dose of the insulin or secretagogue may be necessary. In REIMAGINE 3, where CagriSema was added to basal insulin, no severe low blood sugar was reported.
Class-based: CagriSema already contains semaglutide. The Wegovy label says use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended, and the Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended.
Based on the label of semaglutide, which CagriSema contains (class-based, not a finding for cagrilintide itself): the Wegovy label says semaglutide delays stomach emptying and may affect the absorption of medicines taken by mouth, and says to consider increased clinical or laboratory monitoring with oral medicines that have a narrow therapeutic index or need clinical monitoring. A study of how CagriSema affects warfarin and atorvastatin is listed as completed on ClinicalTrials.gov (NCT06289504), but no results are posted or published.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is CagriSema or cagrilintide FDA-approved?⌄
No. As of November 19, 2026, neither appears among FDA's approved drugs, and FDA states that cagrilintide is not a component of any FDA-approved drug and has not been found safe and effective for any condition. Semaglutide, the other drug in CagriSema, is approved on its own. Only FDA can decide whether the combination is approved.
Is it legal to buy cagrilintide online?⌄
Cagrilintide is an unapproved drug, and FDA says it cannot be used in compounding under federal law. FDA urges consumers to be vigilant when buying drugs online and warns that illegally marketed GLP-1 drugs may be counterfeit or contain the wrong ingredients or amount. A registered clinical trial is the only legitimate way to receive it now.
How does CagriSema compare with semaglutide alone?⌄
In REDEFINE 5, a 68-week trial in Japan and Taiwan, average weight loss was 18.4% on CagriSema and 11.9% on semaglutide alone. In REIMAGINE 2, in type 2 diabetes, HbA1c fell slightly more with CagriSema (1.91 vs 1.75 percentage points). A head-to-head trial against tirzepatide in obesity is listed as completed on ClinicalTrials.gov (NCT06131437), but no results paper was found on PubMed as of November 19, 2026.
Can I join a CagriSema or cagrilintide trial?⌄
Trials are listed on ClinicalTrials.gov, including some still recruiting, such as a trial in children and adolescents, and a trial in high blood pressure that is listed as not yet recruiting. Each trial has its own entry rules. Your doctor can help you judge whether a trial fits you.
Can I take it with my supplements or other medicines?⌄
No interaction studies of cagrilintide with supplements have been published. Because CagriSema contains semaglutide, the semaglutide label applies: low blood sugar is a risk with insulin or sulfonylureas, the labels say using it with another GLP-1 medicine is not recommended, and slower stomach emptying may affect medicines taken by mouth. Ask a doctor or pharmacist to check your own list.
References by claim
weight loss in adults with obesity without diabetes
weight loss in adults with type 2 diabetes
Davies et al., 2025 · PubMed (2025) link
blood sugar (HbA1c) in type 2 diabetes
weight loss with cagrilintide alone
Lau et al., 2021 · PubMed (2021) link
Safety
Interaction: Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide or other GLP-1 medicines
Zepbound (tirzepatide) prescribing information · DailyMed (FDA label) link
Interaction: Oral medicines with a narrow safety margin
ClinicalTrials.gov record NCT06289504: effect of CagriSema on atorvastatin and warfarin levels · ClinicalTrials.gov link
Track Cagrilintide (CagriSema) with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
